Preclinical investigation on the anti-atherosclerotic effects of Tenuifolin via modulation of endothelial–mesenchymal transition in animal models
Cellular Signalling · 2027-01 · 149 · 112894
DOI: 10.1016/j.cellsig.2026.112894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2027-01. Verfasst von Xuemei Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Department, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China; Drug Resea…. Die Arbeit nennt 66 Literaturangaben. Gefördert von: Southwest Medical University, Sichuan Provincial Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
BACKGROUND: Atherosclerosis (AS) has emerged as a leading contributor to the global burden of cardiovascular disease. Consequently, identifying effective and safe therapeutic candidates targeting the pathophysiology of AS is of paramount importance for improving treatment outcomes. Tenuifolin (TEN), a triterpenoid compound isolated from Polygala tenuifolia, exhibits a wide array of pharmacological activities, including neuroprotection, immunomodulatio, and pulmonary protection. However, there is currently a paucity of evidence substantiating the therapeutic efficacy and underlying pharmacological mechanisms of TEN in the management of AS. Therefore, this study aims to systematically evaluate the therapeutic potential of TEN in AS and investigate its associated pharmacological mechanisms. METHOD: ApoE-/- mice were fed a high-fat diet (HFD) to establish an in vivo AS model and were treated with TEN. The effects of TEN on atherosclerotic lesions, lipid metabolism, inflammation, and EndMT were evaluated using serological assays, histological staining, immunofluorescence, metabolomics, and targeted UHPLC-Orbitrap HRMS analysis. The underlying mechanism was further explored by molecular dynamics simulations and in vitro experiments using ox-LDL-stimulated HUVECs. RESULT: TEN treatment markedly alleviated HFD-induced atherosclerotic lesions, reduced lipid deposition, improved serum lipid profiles, and attenuated vascular inflammation and fibrosis. Metabolomic analysis further supported the beneficial effects of TEN on AS-associated metabolic disturbances. Targeted UHPLC-Orbitrap HRMS confirmed that TEN was detectable in whole-aorta homogenates after administration, supporting aortic tissue exposure. In both HFD-induced mice and ox-LDL-treated HUVECs, TEN attenuated EndMT-associated changes, as evidenced by increased endothelial markers CD31 and VE-cadherin and decreased mesenchymal markers α-SMA, FSP1, and fibronectin. Mechanistically, TEN suppressed STAT1 phosphorylation, potentially through modulation of the JAK1/STAT1 signaling axis. CONCLUSION: TEN exerts protective effects against experimental AS, at least partly by attenuating EndMT-associated vascular remodeling through suppression of JAK1/STAT1 signaling. These findings suggest that TEN may serve as a promising therapeutic candidate for AS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Geriatric Department, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China; Drug Research Center of Integrated Traditional Chinese and Western Medicine, The…
- Department of Hematology, Suizhou Hospital, Hubei University of Medicine, Suizhou 441300, Hubei, China.
- Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China; Institute of Integrated Chi…
- Institute of Integrated Chinese and Western Medicine, Southwest Medical University, Luzhou 646000, Sichuan, China.
- Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China.
- Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China; Luzhou Key Laboratory of re…
Förderung
- Southwest Medical University
- Sichuan Provincial Administration of Traditional Chinese Medicine
Zitieren
APA
Yang, X., Wang, F., Bi, T., Chen, L., Wang, T., Huang, J., Dai, X., Zhao, Q., Yao, S., Sun, Q., Liu, Z., & Xu, H. (2027). Preclinical investigation on the anti-atherosclerotic effects of Tenuifolin via modulation of endothelial–mesenchymal transition in animal models. Cellular Signalling, 149, 112894. https://doi.org/10.1016/j.cellsig.2026.112894
Vancouver
Yang X, Wang F, Bi T, Chen L, Wang T, Huang J, et al. Preclinical investigation on the anti-atherosclerotic effects of Tenuifolin via modulation of endothelial–mesenchymal transition in animal models. Cellular Signalling. 2027;149:112894. doi:10.1016/j.cellsig.2026.112894
BibTeX
@article{Yang2027,
author = {Yang, Xuemei and Wang, Fan and Bi, Tao and Chen, Lei and Wang, Ting and Huang, Juan and Dai, Xiyu and Zhao, Qixin and Yao, Shengdan and Sun, Qin and Liu, Zengjin and Xu, Houping},
title = {Preclinical investigation on the anti-atherosclerotic effects of Tenuifolin via modulation of endothelial–mesenchymal transition in animal models},
journal = {Cellular Signalling},
year = {2027},
volume = {149},
pages = {112894},
doi = {10.1016/j.cellsig.2026.112894}
}
EUVIMED